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ABSTRACT - Background: Gastric cancer is the fifth most frequent cancer and the third most 
common cause of cancer-related deaths worldwide.It has been reported that Wnt/ betacatenin 
pathway is activated in 30-50% of these tumors. However,the deregulation of this pathway 
has not been fully elucidated. Aim: To determine the expression of E-cadherin, betacatenin, 
APC, TCF-4 and survivin proteins in gastric adenocarcinoma tissues and correlate with clinical 
and pathological parameters. Method: Seventy-one patients with gastric adenocarcinoma 
undergoing gastrectomy were enrolled. The expression of E-cadherin, betacatenin, APC, TCF-
4 and survivin proteins was detected by immunohistochemistryand related to the clinical 
and pathological parameters. Results: The expression rates of E-cadherin in the membrane 
was 3%; betacatenin in the cytoplasm and nucleus were 23,4% and 3,1% respectively; APC 
in the cytoplasm was 94,6%; TCF-4 in the nucleus was 19,4%; and survivin in the nucleus 
93,9%. The expression rate of E-cadherin was correlated with older patients (p=0,007), while 
betacatenin with tumors <5 cm (p=0,041) and APC with proximal tumors (p=0,047). Moreover, 
the expression of TCF-4 was significantly higher in the diffuse type (p=0,017) and T4 tumors 
(p=0,002).Conclusion: The Wnt/betacatenin is not involved in gastric carcinogenesis. However, 
the high frequency of survivin allows to suggest that other signaling pathways must be involved 
in the transformation of gastric tissue. 
RESUMO - Racional: O câncer gástrico encontra-se entre as principais neoplasias malignas do mundo 
sendo o quinto mais incidente e o terceiro em relação ao índice de mortalidade. Acredita-se que a 
via Wnt/betacatenina esteja ativada em 30-50% desses tumores, porém a desregulação dela ainda 
não está completamente esclarecida. Objetivo: Avaliar a imunoexpressão das proteínas E-caderina, 
betacatenina, APC, TCF-4 e survivina em tecidos de adenocarcinoma gástrico e correlacioná-las com 
as variáveis clínicas dos doentes e anatomopatológicas do tumor. Método: Foram coletados os 
dados clínicos e anatomopatológicos dos prontuários de 71 doentes com adenocarcinoma gástrico 
submetidos à gastrectomia. O material obtido na operação foi submetido à análise imunoistoquímica 
e a frequência da expressão de cada proteína pôde ser analisada de acordo com a sua localização 
na célula e relacionada com as variáveis clinicopatológicas. Resultados: A graduação percentualda 
expressão e da localização das proteínas foi a seguinte: E-caderina em 3% na membrana; betacatenina 
em 23,4% no citoplasma e 3,1% no núcleo; APC em 94,6% no citoplasma; TCF-4 em19,4% no núcleo; 
e survivina em 93,9% no núcleo. Houve relação entre expressão da proteína E-caderina com a 
idade mais avançada (p=0,007); betacatenina com tumores <5 cm de diâmetro (p=0,041);APC com 
tumores proximais (p=0,047); eTCF-4 com tipo difuso da classificação de Lauren (p=0,017) e com o 
grau de penetração tumoral (p=0,002). Conclusão: A via Wnt/betacatenina não está envolvida na 
carcinogênese gástrica. Porém, a frequência elevada de survivina permite sugerir que outras vias 
sinalizadoras devam estar envolvidas na transformação do tecido gástrico.
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INTRODUCTION
Gastric cancer (GC) is the fifth most frequent cancer and the third most common cause of cancer-related deaths worldwide11. More than 70% of cases occurred in developing countries and Brazilian estimates for the 
year 2016 by the National Cancer Institute are 20,520 new cases14.
The complete resection is the only way to cure GC but approximately 75% of 
these patients are diagnosed at an advanced stage and cannot be cured merely by 
surgery, so chemotherapy combined with surgery is often required5. Despite recent 
advances in diagnostic methods, surgical techniques, chemotherapy regimens and 
targeted therapy, more than half recur16. In addition, the prognosis of patients with 
advanced GC remains relatively poor with a median overall survival of 12 months 
in Western countries28.
An understanding of the pathogenic mechanisms and the different pathways may 
be critical for improvements in the diagnosis, treatment or prediction of prognosis 
of GC. The progression into an invasive cancer is a complex multifactorial process 
with genetic and epigenetic changes affecting several signaling pathway such as 
Wnt/ betacatenin15. 
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Wnt/betacatenin pathway is a conserved molecular 
system that plays a major role in embryogenesis and tissue 
homeostasis, as well as tumorigenesis8. The activity of this 
pathway is dependent on the amount of betacatenin in the 
cytoplasm. Normally, the level of cytoplasmic β-catenin is 
maintained low through ubiquitin-proteasome-mediated 
degradation, regulated by a multiprotein “destruction” 
complex containing the core protein axin, adenomatous 
polyposis coli (APC), glycogen synthase kinase-3beta (GSK-
3beta) and casein kinase 1 (CK1)17. In addition, betacatenin 
can also be detected in the membrane, integrated with a 
transmembrane glycoprotein E-cadherin forming a complex 
that play a key role in the maintenance of cell/cell adhesion 
in epithelial tissues13. It well known that loss of E-cadherin 
expression enhances cell migration and promotes metastasis9. 
The binding of Wnt proteins to a membrane receptor 
complex comprised of Frizzled/low-density lipoprotein 
receptor-related protein (Fzd/LRP) initiates a signaling cascade, 
activating and recruiting disheveled (Dsh) and AXIN to the 
membrane, thereby disrupting the destruction complex. As 
a result, free no phosphorylated betacatenin accumulates 
in the cytoplasm and translocates into the nucleus. In the 
nucleus, β-catenin displaces Groucho, binds T cell factor/
lymphoid enhancer factor (TCF/LEF) and initiates transcription 
of its target genes as survivin25. 
It has been reported that aberrant Wnt/ betacatenin 
signaling is widely implicated in diverse human malignancies 
including GC 2,7,22. The nuclear accumulation of betacatenin, 
a hallmark of Wnt signaling activation, is found in more 
than 50% of gastric cancers6. However, the mechanisms that 
promote deregulation of the Wnt pathway in GC are still not 
completely understood10.
To study the influence of Wnt in CG, was proposed 
to evaluate the expression of E-cadherin, betactenin, APC, 
TCF-4 and survivin proteins in gastric carcinoma tissues and 
correlate with clinico-pathological parameters.
METHODS
The Ethic Review Committee at Universidade Federal de 
São Paulo (UNIFESP) approved the study protocol (Registration 
no 834.176).
Patients 
A total of 74 specimens of primary gastric carcinomas 
(GC) were collected from patients who underwent radical 
surgical resection at the Department of General Surgery of 
Faculdade de Medicina ABC (SP, Brazil) from January 2007 to 
December 2010. The patients’ medical records were reviewed 
to determine their age, gender, anatomical site, tumor size, 
histological grade and the presence or absence of lymphatic, 
vascular or neural invasion. The inclusion criteria were patients 
aged over 18 years, of both genders, whom had undergone 
curative or palliative gastrectomy without neoadjuvant radio 
or chemotherapy, with histological examination confirming 
gastric carcinoma. Three patients were excluded because 
their paraffin blocks were unsuitable for histopathology and 
immunohistochemistry.
TMA construction
TMA blocks also called receptor block were constructed 
at the laboratory of Pathology Department of Faculdade 
de Medicina da Universidade de São Paulo. For this, the 
paraffin blocks containing the tissue of gastric cancer from 
the Department of Pathology of Faculdade de Medicina do 
ABC were used.
Representative areas selected by a pathologist of the 
71 gastric carcinomas were selected from hematoxylin-
eosin stained sections. The selected area was marked in the 
respective paraffin block. A cylindrical core was created in the 
receptor block using using Beecher™ equipment (Beecher 
Instruments, Silver Spring, MD, USA). A 1 mm cylinder of tissue 
was extracted from the selected area of the donating block 
and was transferred to the core in the receptor block. New 
core positions were created in the receptor block, separated 
by fractions of 1 mm such that a collection of tissue samples 
was created following the matrix arrangement.
Immunohistochemistry
Immunohistochemistry methods were performed at 
Experimental Molecular Pathology Laboratory I Department 
of Pathology for evaluating the expression of E-cadherin, 
betacatenin, APC, TCF-4 and survivin.
Slides of 3 µm were obtained from TMA block and 
mounted pretreated with 3-minopropyl-triethoxysilane 
(Sigma, St. Louis, MO, USA). Sections were deparaffinized 
in three changes of xylene and hydrated in a graded series 
of ethanol finishing in distillated water. For antigen retrieval 
slides were placed in 0,01M citrate-buffer pH 6,0 and heated 
in a steamer for 30 min. Endogenous peroxidase was blocked 
by using 10% hydrogen peroxide for 20 min. The slides were 
then washed in distillated water and phosphate buffer saline 
(PBS) and incubated overnight with the following monoclonal 
igG antibodies: betacatenin (E5 sc-7963, dilution 1:200, Santa 
Cruz, California, USA); E-cadherin (H-108 sc-7870, dilution 
1:100, Santa Cruz, California, USA); APC (C-20 sc-896, dilution 
1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA); TCF-4 
(H-125 sc-13027, dilution 1:100, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA); survivin (FL-142 sc-10811, dilution 
1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Subsequently, slides were washed with PBS and incubated 
with biotinylated secondary antibody for 30 min, washed 
with PBS, and incubated with streptavidin-biotin-peroxidase 
(LSAB kit, Dako, USA) for 30 min each.
Finally, the reaction was revealed using 3,3’-diaminobenzidine 
tetrahydrocloride (Kit DAB-Sigma, Sigma-Aldrich, St. Louis, 
MO, USA) and counterstained with Harris’s hematoxylin and 
coverslipped with Entellan (Merck KGaA, Darmstadt, GER). 
Negative and positive controls were made to run simultaneously.
The positive pattern for E-cadherin (membrane and 
cytoplasm), betacatenin (membrane, cytoplasm, nucleus), APC 
(cytoplasm and nucleus), TCF-4 (cytoplasm and nucleus), survivin 
(cytoplasm and nucleus) were noted. As a positive control of 
the reactions, a histological cut of colon adenocarcinoma was 
used, which proved to be positive for the studied proteins.
Evaluation
Two trained researchers evaluated the expression of each 
protein independently and they were blinded to the clinico-
pathological parameters. They analyzed the percentage of 
positive cells and staining intensity. The percentage score of 
positive cells was classified semi-quantitatively as follows: 0, 
≤10% of positive cells; 1, between 11-25% of positive cells; 
2, between 26-50% of positive cells; and 3, >50% of positive 
cells. The intensity score was graded as follows: 0, no brown 
in the cells; 1, light brown in the cells; 2, brown in the cells; 
and 3, strong brown in the cells. The overall score (OS) was 
calculated by the multiplication of percentage score and the 
intensity score. A patient with OS higher or equal than 4 was 
defined as positive for the expression of the protein and those 
with scores less than 4 negative.
Statistical analysis 
The relationships between the immunohistochemical 
status of E-cadherin, betacatenin, APC, TCF-4 and survivin 
with various clinico-pathological findings were evaluated. 
Continuous data were compared by Mann-Whitney U test. 
Categorical analysis of variables was performed by Fisher’s 
exact test. A p<0.05 was considered statiscally significant.
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expression of betacatenin than in the group with negative 
expression (p=0.041). Analyzing the group of tumors with 
positive expression of betacatenin in the cytoplasm, there 
was 3.65 times more chance to be ≤5 cm (p=0.034 [1.07 to 
12.42]). At the nucleus, there was no significant association 
between betacatenin and clinico-pathological parameters. 
About APC in the cytoplasm, it was noted that all proximal 
tumors showed positive expression (p=0.047). In relation 
to TCF-4 in the nucleus, there was an association between 
positive expression and pT (p=0.002). Tumors with positive 
expression showed 12.00 times more chance to be pT4 (p=0.003 
[1.79 to 80.61]) and 10.50 times more chance to be in the 
group pT0+ 1 + 2 (p=0.002 [1.91 to 57.59]) than to be pT3. 
Moreover, was noted the association with the diffuse type 
tumors (p=0.017) and the tumors with positive expression 
of TCF-4 in the nucleus, showed 5.05 times more likely to 
be diffuse type of Lauren than the intestinal type (p=0.009 
[1.40 to 10.14]). Finally, it can be considered that there was 
a trend of the association between the positive expression 
of survivin and intestinal type of Lauren tumors (p=0.091), 
because tumors with positive expression of survivin in the 
nucleus and/or cytoplasm showed 7.33 times more likely to 
be intestinal type of Lauren (p=0.050 [0.71 to 75.27]).
DISCUSSION
In the present study, was found a positive expression 
of E-cadherin at the membrane in only 3% of cases unrelated 
to the parameters analyzed. This result is lower than that 
described in the literature ranging from 32 to 60.9% and 
demonstrates the relationship with high-grade tumors and 
lymph node involvement18, 20. However, in the cytoplasm, was 
noted the expressed E-cadherin positive in 63.6% of cases. 
Thus, a hypothesis that may explain this difference found 
is that most of these studies conducted a joint analysis of 
E-cadherin expression in the membrane and cytoplasm.
Despite the low prevalence of E-cadherin in the membrane, 
was found the presence of betacatenin in the membrane in 
29.7% of cases being more prevalent in females. Grabsch et al. 
reported the presence of betacatenin in 13.5% of cases and 
realized a combination of 93.2% between the simultaneous 
absence of betacatenin and E-cadherin in the membrane. 
However, Guerfali et al. found the prevalence of 61.3% and 
reported that the cases where there was loss of membrane 
expression of betacatenina and E-cadherin were associated 
with poorly differentiated tumors.
In the cytoplasm, was found the positive expression of 
betacatenin and APC in 23.4% and 94% of cases respectively. 
Betacatenin had relationship with tumors smaller than 5 cm 
and all proximal tumors showed positive expression of APC. 
The result obtained regarding APC was greater than that 
found for Ayed-Guerfali et al. (68.7%) that differently, showed 
no relationship with clinico-pathological data they studied. 
The finding of this sample suggests that the expression of 
APC protein was not involved in GC carcinogenesis, probably 
because their function was preserved without altering the 
functioning of the degradation complex, maintaining the 
betacatenin in the cytoplasm at physiological levels.
At the nucleus, was found the expression of betacatenin 
in 2 patients (3.1% of cases), with no significant relationship 
with the parameters analyzed, but the two were intestinal 
type by Lauren classification. Ayed-Guerfali et al. showed 
almost the same prevalence (3.75%), and using another 
evaluation criteria that considered abnormal the cases where 
betacatenin was not expressed or was expressed mainly in the 
nucleus and/or the cytoplasm, demonstrated the relationship 
between the abnormal pattern and patients in stages III 
and IV and with lymph node metastasis. Miyazawa et al. 
also found the expression of betacatenin only in intestinal 
RESULTS
Of the 71 patients with gastric adenocarcinoma analyzed, 
64.8% were men and 60.6% were older than 60 years.
The morphologic characteristics of gastric carcinoma 
are shown in Table 1. It was found that 63.4% of the tumors 
were located in the proximal region and that 54.3% had a 
diameter greater than 5 cm. Regarding the degree of cell 
differentiation, 55.9% were well or moderately differentiated, 
69% were intestinal type and the presence of venous, 
lymphatic and perineural was found in 33.3%, 56.5% and 
62.3 % of cases, respectively.
TABLE 1 - Morphologic characteristics of gastric carcinoma
Parameters n (%)
Anatomical site Distal 26 (36,6)Proximal 45 (63,4)
Tumor size <5 cm 32 (45,7)
>5 cm 38 (54,3)
Lauren type Intestinal 49 (69)
Diffuse 22 (31)
Differentiation
Moderate + well differentiate 38 (55,9)
Poor 30 (44,1)
pT
0 + 1 + 2 20 (28,1)
3 41 (57,7)
4 10 (14,1)
pN 0 25 (35,2)
1+2+3 46 (64,8)
Vascular invasion Absence 46 (66,7)Presence 23 (33,3)
Lymphatic 
invasion
Absence 30 (43,5)
Presence 39 (56,5)
Neural invasion Absence 26 (37,7)Presence 43 (62,3)
n=number of cases
The frequency of immunostaining of studied proteins 
was: E-cadherin 3% in the membrane; betacatenina 29.7% 
in the membrane, 23.4% in the cytoplasm and 3.1% in the 
nucleus, APC 94.6% in cytoplasm, TCF-4 19.4% in nucleus 
and survivin 93.9% in nucleus (Table 2)
TABLE 2 - Immunohistochemical expression of E-cadherin, 
betacatenin, APC, TCF-4 and survivin in gastric cancer
Proteins Negative n (%) Positive n (%)
E-cadherin Membrane 64 (97) 2 (3)Cytoplasm 24 (36,4) 42 (63,6)
Betacatenin
Membrane 45 (70,3) 19 (29,7)
Cytoplasm 49 (76,6) 15 (23,4)
Nucleus 62 (96,9) 2 (3,1)
APC Citoplasm 3 (5,1) 56 (94,6)Nucleus 6 (10,2) 53 (89,8%)
TCF-4 Cytoplasm 50 (74,6) 17 (25,4)Nucleus 54 (80,6) 13 (19,4)
Survivin Cytoplasm 4 (6,1) 62 (93,9)Nucleus 4 (6,1) 62 (93,9)
n= number of cases
The relationship between the clinico-pathologic 
parameters and immunohistochemical expression of the 
proteins is exposed in Table 3. Regarding the expression of 
betacatenin in the membrane, more women were noted in 
the group of tumors with betacatenin positive than negative 
(p=0.024). Considering only the group of tumors with 
betacatenin in the membrane positive, there was 3.78 times 
more chance to involve women than men (p=0.018 [1.23-
11.65]). For betacatenin expression in the cytoplasm, there was 
a greater number of tumors ≤5 cm in the group with positive 
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type by Lauren and Grabsch et al. analyzing 401 gastric 
adenocarcinomas found that 6.5% of them had betacatenin 
strongly expressed in the nucleus and were associated with 
the intestinal type of Lauren. However, most authors reported 
a higher prevalence of betacatenin in GC, such as: Ohene-
Abuakwa et al. 34%, Woo et al. 27%, and Yu et al. 15.1%. 
The variation found between the results probably occurs 
due to different testing methods and criteria used, as well 
as the discrepancy between the sample sizes of each study. 
Nevertheless, most of these studies could demonstrate a 
correlation between the betacatenin cellular expression 
and any clinico-pathological parameters, highlighting the 
importance of betacatenin in the GC tumorigenic process. 
However, the underlying molecular mechanisms leading to 
activation of the signaling pathway mediated by betacatenin 
still need to be clarified.
In relation to TCF-4 protein, this study showed positive 
expression in the nucleus in 19.4% of cases, values  below 
those reported by Yu et al. who were 86.5%. This difference 
probably is justified because we use more stringent criteria 
that only considered the expression positive when the score 
obtained by the product of the intensity and the area was 
greater than or equal to 4, while these authors considered 
positive when different from zero. Moreover, was observed 
relationship between the nuclear expression of TCF-4 and 
T4 tumors and diffuse type of Lauren tumors, while Yu et 
al. described relationship with the intestinal type. Is known 
that the nuclear TCF-4 has a major role in the last step of 
the canonical Wnt signaling by interacting with the nuclear 
betacatenin and trigger the transcription of target genes25. 
Thus, the low frequency of nuclear positive TCF-4 and 
betacatenin expression found in the present study suggests 
that the canonical pathway would not be involved in gastric 
carcinogenesis.
Survivin is a genetic target of the Wnt pathway and 
has its expression increased by betacatenin4. However, 
in this study was found no relationship between survivin 
and betacatenin expression, both in the nucleus and the 
cytoplasm. In this series survivin protein showed the same 
positive expression (93.9%) in the nucleus and the cytoplasm, 
and as Lu et al. has shown to be related to intestinal type 
tumors. Its molecular regulation mechanism is not well 
defined and there is controversy in the literature regarding 
its expression in GC. Song et al. analyzed 157 patients with 
stage III GC and found survivin nuclear expression in 40.1% 
of cases with predominance of tumors larger than 5 cm. 
Patients with negative immunoreactivity of survivin showed 
significantly higher survival24. Bury et al. found survivin 
expressed in 73.17% of patients and showed that carcinomas 
without survivin expression had lower incidence of distant 
metastasis and improved survival at 1, 2 and 3 years. Shintani 
et al. reported the presence of survivin in the cytoplasm 
andthe nucleus in 35% and 49% respectively. Moreover, 
they found a relationship between the nuclear expression 
of survivin and well/moderate differentiated gastric tumors. 
With the results found in this study, it can be reinforced the 
importance of survivin in GC carcinogenesis and suggest the 
possibility of it being stimulated by other pathway than the 
Wnt/betacatenin.
It´s known that the immunohistochemical evaluation 
offers several advantages but we are aware of the limitations 
of this approach. Changes in immunostaining are neither 
completely sensitive nor specific for changes in protein 
expression. Furthermore, immunohistochemistry does not 
provide direct information about the changed protein 
function. Studies examining the genetic and epigenetic 
events are needed.
However, in this study, the low frequency of positive 
E-cadherin expression in the membrane, without the consequent 
accumulation of betacatenin in the cytoplasm and/or nucleus, 
TABLE 3 - Relationship between clinico-pathological parameters and immunohistochemical expression ofE-cadherin, 
β-catenin, APC, TCF-4 and survivin in GC patients
Parameters E-Cad. memb. n(%)
Betacat. 
memb. n(%)
Betacat. 
cytopl. n(%)
Βetacat.
nucleus n(%)
APC Cytopl. 
n(%)
TCF-4 
Nucleus n(%)
Survivin 
nucleus n(%)
Gender
 Male 0 (0) 8 (42,1) 7 (46,7) 1 (50%) 37 (66,1) 11 (84,6) 41 (66,1)
 Female 2 (100) 11(57,9) 8 (53,3) 1 (50%) 19 (33,9) 2 (15,4) 21 (33,9)
 p value * 0,098 0,024 0,098 1,000 1,000 0,192 0,606
Age (years)
<60 0 (0) 8 (42,1) 6 (40) 0 (0) 18 (32,1) 7 (53,8) 23 (37,1)
>60 2 (100) 11 (57,9) 9 (60) 2 (100) 38 (67,9) 6 (46,2) 39 (62,9)
p value ** 0,515 0,574 0,764 0,532 0,263 0,209 0,292
Anatomical site
 Distal 0 (0) 6 (31,6) 3 (20) 0 (0%) 19 (33,9) 6 (46,2) 22 (35,5)
 Proximal 2 (100) 13 (68,4) 12 (80) 2 (100%) 37 (66,1) 7 (53,8) 40 (64,5)
p value * 0,530 0,778 0,220 0,532 0,047 0,521 0,618
Size (cm)
 <5 2 (100) 9 (50) 10 (66,7) 1 (50%) 23 (41,8) 8 (61,5) 29 (47,5)
 >5 0 (0) 9 (50) 5 (33,3) 1 (50%) 32 (58,2) 5 (38,5) 32 (52,5)
p value * 0,195 0,576 0,041 1,000 1,000 0,227 0,122
Lauren type
 Intestinal 2 (100) 7 (36,8) 12 (80) 2 (100%) 39 (69,6) 5 (38,5) 44 (71)
 Diffuse 0 (0) 12 63,2) 3 (20) 0 (0%) 17 (30,4) 8 (61,5) 18 (29)
p value * 1,000 0,564 0,525 1,000 0,287 0,017 0,091
Differentiation
 Mod-Well 2 (100) 13 (76,5) 11 (73,3) 2 (100%) 31 (58,5) 6 (46,2) 35 (58,3)
 Poor 0 (0) 4 (23,5) 4 (26,7) 0 (0%) 22 (41,5) 7 (53,8) 25 (41,7)
 p value * 0,492 0,085 0,230 0,503 0,571 0,365 0,082
pT
 0 + 1 + 2 0 (0) 6 (31,6) 5 (33,4) 1 (50%) 13 (23,2) 7 (53,9) 16 (25,8)
 3 2 (100) 11 (57,9) 8 (53,3) 0 (0%) 35 (62,5) 2 (15,4) 36 (58,1)
 4 0 (0) 2 (10,5) 2 (13,3) 1 (50%) 8 (14,3) 4 (30,8) 10 (16,1)
 p value * 1,000 0,544 0,647 0,149 0,335 0,002 1,000
pN
 0 0 (0) 7 (36,8) 5 (33,3) 1 (50%) 19 (33,9) 5 (38,5) 21 (33,9)
 1+2+3 2 (100) 12 63,2) 10 (66,7) 1 (50%) 37 (66,1) 8 (61,5) 41 (66,1)
 p value * 1,000 0,564 1,000 0,531 0,287 1,000 0,298
Vascular Invasion
 Absence 1 (50) 13 (72,2) 11 (73,3) 2 (100%) 35 (64,8) 8 (61,5) 39 (65)
 Presence 1 (50) 5 (27,8) 4 (26,7) 0 (0%) 19 (35,2) 5 (38,5) 21 (35)
p value * 1,000 0,561 0,541 0,535 0,544 0,742 0,614
Lymphatic Invasion 
 Absence 1 (50) 9 (50) 7 (46,7) 1 (50%) 23 (42,6) 5 (38,5) 24 (40)
 Presence 1 (50) 9 (50) 8 (53,3) 1 (50%) 31 (57,4) 8 (61,5) 36 (60)
p value * 1,000 0,265 0,548 1,000 0,576 0,759 1,000
Neural Invasion 
 Absence 0 (0) 9 (50) 6 (40) 1 (50%) 20 (37) 5 (38,5) 22 (36,7)
 Presence 2 (100) 9 (50) 9 (60) 1 (50%) 34 (63) 8 (61,5) 38 (63,3)
p value * 0,542 0,265 1,000 1,000 0,553 1,000 1,000
E-cad.=E-cadherin; Betacat=betacatenin; APC=adenomatous polyposis coli; TCF-4=T-cell factor; Memb=membrane; Cytopl.=cytoplasm; n=number of cases; Mod-
Well=moderate/well differentiate; Poor=poor differentiate; * Fisher test; ** Mann-Whitney test
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suggesting that the effect of E-cadherin protein does not 
induce activation of Wnt pathway. Furthermore, the high 
frequency of positive cytoplasmatic APC expression associated 
with low frequency of positive cytoplasmatic and nuclear 
betacatenin expression, suggesting a low prevalence of 
mutations in the APC gene in GC and betacatenin degradation 
via ubiquitination be occurring normally. Finally, the high 
frequency of nuclear survivin expression associated with 
low frequency of positive nuclear betacatenin and TCF-4 
expressions, suggests that the canonical pathway was not 
activated in the GC, there is probably another parallel pathway 
responsible for the survivin production.
These results may contribute to a better understanding 
of this signaling pathway in gastric carcinogenesis and 
to identify possible targets such as the reduction of the 
survivin gene expression, for the development of drugs for 
GC treatment.
CONCLUSION
Wnt/beta-catenin is not involved in gastric carcinogenesis. 
However, the high frequency of survivin allows to suggest 
that other signaling pathways must be involved in the 
transformation of gastric tissue.
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